Highlights: 10 subjects in cohort six intravenously dosed with RECCE® 327 at 4,000mg demonstrated good safety and tolerabilityIndependent Safety Committee...
- Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases...
Multicenter Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 for relapsed or refractory B-NHL and CLL under...
- This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug...
- IND submission of a novel α7β1 integrin activating allosteric antibody anticipated by year end 2022 SOUTH SAN FRANCISCO, Calif.,...
Boca Raton, Florida, June 22, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused...
-Similar significant reductions of hepatitis B virus (HBV) DNA and HBV RNA observed following 28 days of daily oral ALG-000184...
Leverages $32 million Series B funding to speed up manufacturing, grow workforce, and build key partnerships for autonomous microtomy Clarapath...
Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free SurvivalNEWARK, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- CymaBay...
Leading Center of Excellence will participate in a 60-day evaluation of The Company’s signal processing technologyWestport, CT, June 22, 2022...
Initial A4100 code being deployed and application for specific HCPCS product code to be submitted in the second calendar quarterFRAMINGHAM,...
Prospective multicenter trial for the Unyvero UTI panel recruited its 1,000th prospective patient sampleFourth trial site added to optimize enrollment...
TORONTO, June 22, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”),...
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of...
- These results are the first reported demonstration of rapid and robust treatment changes in key disease markers associated with...
MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy...
BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...
--Cash runway extended late into calendar Q2 2023 --Tumor control achieved following MDNA11 treatment in 3 out of 8 patients...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or...